76 results
8-K
EX-99.1
GRTS
Gritstone Bio Inc
9 May 24
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:07pm
, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 --
-- Nature Medicine publication of Phase 1 … other programs and capabilities is also encouraging. The recent paper in Nature Medicine highlights the scientific rigor with which we built our
8-K
EX-99.1
GRTS
Gritstone Bio Inc
9 Aug 23
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
4:08pm
--
-- Publication in Nature Communications of interim CORAL-BOOST results highlights the potential of Gritstone’s self-amplifying mRNA (samRNA) candidates … the differentiation and potential advantages of self-amplifying mRNA (samRNA) over current vaccines against infectious diseases. Our recent publication in Nature
8-K
GRTS
Gritstone Bio Inc
1 Feb 21
Entry into a Material Definitive Agreement
5:03pm
, and information sharing provisions in favor of each party that are customary for an agreement of this nature.
In connection with the Collaboration … each party that are customary for an agreement of this nature.
The foregoing summaries of the Collaboration Agreement, Purchase Agreement
8-K
EX-99.1
GRTS
Gritstone Bio Inc
4 Aug 22
Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
4:41pm
effect due to its self-replicating nature, an inherent potential benefit of samRNA compared to first-generation mRNA vaccines. We look forward … samRNA vaccine against SARS-CoV-2 were published in Nature Communications (article here). The results of the study, which were previously pre-printed
8-K
EX-99.1
GRTS
Gritstone Bio Inc
3 Nov 22
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
4:08pm
of the GRANITE program, common to SLATE, are illuminated in our recent publication of GRANITE Phase 1/2 results in Nature Medicine. This technology platform … the Phase 1/2 trial of GRANITE were published in Nature Medicine (here). The paper describes how Gritstone’s neoantigen-directed vaccination approach
DRS/A
EX-10
zdyqr9w
9 Jul 18
Draft registration statement (amended)
12:00am
8-K
nd1o256dt44li
22 Jan 21
Entry into a Material Definitive Agreement
4:16pm
DRS/A
EX-10
5ix64yyl 0qa525jb
9 Jul 18
Draft registration statement (amended)
12:00am
8-K
0xq2hs z5zdpi
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
DRS/A
EX-10
vzdh0 w2pz1gy0r3ki
9 Jul 18
Draft registration statement (amended)
12:00am
8-K
EX-99.1
jqqbeqo7s9rn7s ief4v
13 Jan 20
Other Events
6:15am
DRS/A
EX-10
77f57wux8s21y2ide2z
9 Jul 18
Draft registration statement (amended)
12:00am
8-K
EX-10.1
cjet7d3n
29 Sep 21
Entry into a Material Definitive Agreement
4:24pm
10-K
EX-10.9
lhqb8q3ggv3v69
28 Mar 19
Annual report
4:01pm
DRS/A
EX-10
gxyzwhb1ri8
9 Jul 18
Draft registration statement (amended)
12:00am
8-K
EX-10.1
mgu6r rcz
5 Feb 19
Entry into a Material Definitive Agreement
4:21pm
8-K
EX-10.1
9y7eltwcy9v 5qa
6 Apr 23
Entry into a Material Definitive Agreement
4:38pm
D
ooa9ok4 hy
22 Oct 21
$55M in equity, sold $55M, 10 investors
4:09pm
D
v3z96emuw5m7cxgp
8 Nov 22
$45.00 mm in equity / options / securities to be acquired, sold $45.00 mm, 6 investors
4:44pm